[1] |
WANG Donghui, JIANG Suwen, HU Airong, ZHU Bo, HE Zheyun, ZHANG Lukan, WANG Jialan, FAN Ying, LIN Ken .
Mulberry exerts antioxidant stress effect in rats with nonalcoholic fatty liver disease
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 609-616.
|
[2] |
WU Xianchuang, LIU Yuxin, NIU Yuji, HE Jinjin, QIAO Hui, ZHANG Leilei.
Mechanism of DCLK1 transcriptional regulation in HCC
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1241-1246.
|
[3] |
MA Shen, LIU Yushuo, TANG Hui, CHEN Wenbin, GAO Ling.
Pharmacokinetics and clinical significance of drugs for improving nonalcoholic fatty liver disease
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(8): 908-918.
|
[4] |
YE Kaili, ZHENG Wen, YE Qifa, YANG Lan .
Mechanism of CDK1 participates in the development of hepatocellular carcinoma and its inhibitor application value
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(9): 1086-1094.
|
[5] |
LIU Wenjing, WU Zhitao, PAN Guoyu.
Early dectection and prediction hepatotoxic risk in vitro
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(8): 923-930.
|
[6] |
YU Saihong, ZHENG Xiaoliang, PU Yiyi, YAN Dongmei, WANG Xiaoju, YU Jie.
Reversal of 5-fluorouracil resistance in hepatocellular carcinoma cells by inhibiting ribonucleotide reductase M2
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(7): 729-737.
|
[7] |
XU Lina, LI Yue, PENG Jinyong.
microRNA and drug-induced liver injury
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(7): 803-809.
|
[8] |
HUANG Kang, LI Ling, YE Qifa, PENG Guizhu.
Expression of long non-coding RNA LINC00844 in hepatocellular carcinoma and its inhibiting effect on cell proliferation and migration
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(4): 366-372.
|
[9] |
CHANG Qingqing, PENG Ying, WANG Guangji, SUN Jianguo.
Clinical research progress of small molecule tyrosine kinase inhibitors as anti-hepatocellular carcinoma agents
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(8): 948-956.
|
[10] |
YANG Shucai,ZHANG Li,LIU Liping,DENG Weijie,ZHOU Jie,LIU Hui,ZHANG Baohu,JIN Tao.
Effect of hypoxia-inducible factor 2α on chemoresistance of hepatocellular carcinoma
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(6): 630-636.
|
[11] |
TIAN Jing, MENG Qiuhua, LIANG Qiuyun, DONG Min.
Research progress in the associations of metabolic diseases and therapeutic drugs with hepatocellular carcinomas
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(1): 103-110.
|
[12] |
CHEN Xi, LING Jiawei, DING Jiaxin, JIANG Zhenzhou, ZHANG Luyong.
Advances in pathogenesis of nonalcoholic fatty liver disease caused by tamoxifen
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(6): 715-720.
|
[13] |
YUAN Gang, HU Airong, HU Yaoren, ZENG Chuanli, ZHU Dedong, SHI Xiaojun.
Clinical efficacy and long-term prognosis of entecavir and adefovir dipivoxil in the treatment of compensatory hepatitis B cirrhosis
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(2): 170-174.
|
[14] |
CAI Min, XU Liu, SHEN Lan, ZHANG Jie.
Expression of long-chain non-coding RNA FOXN3-AS2 in hepatocellular carcinoma and its effect on proliferation and invasion of hepatoma cells
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(11): 1246-1251.
|
[15] |
LI Yun, LI Bingsheng, ZHANG Weifang, LI Yixiu, LI Chun, PENG Juan, LAI Xin, ZHU Jing, XU Ruilai, XIONG Aizhen.
Association study of miR-146a G>C polymorphisms with susceptibility of hepatocellular carcinoma in the Chinese population: a Meta-analysis
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(7): 779-786.
|